Psychedelics spent a half-century in political and medical purgatory. Now they’re starting to go mainstream. Respected academic institutes and billionaires are funding research into their therapeutic benefits, and the Food and Drug Administration could soon approve MDMA (known more commonly as ecstasy) for a treatment for post-traumatic stress disorder. The therapeutic potential of these drugs looks promising, but Wall Street and big pharma are still not convinced of the financial potential.
Read the full article: Psychedelics Are Going Mainstream. Investing in Them Hasn’t. //
Source: https://www.wsj.com/health/pharma/psychedelics-lsd-ketamine-psilocybin-mushrooms-investing-ptsd-d8f05e58